2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2658

Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2659

Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1995

Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: L16

GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2562

Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2689

GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2569

Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: L13

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2317

Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2677

Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1994

Helicobacter Pylori Infection Among Korean Patients with Rheumatoid Arthritis and Its Interaction with Shared Epitope

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2101

Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2406

Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2359

High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis

RA – Treatments Poster III: Safety and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].